Public Event Detail
Monashee Investment Management LLC Sells 25,000 Shares of Cytokinetics, Incorporated $CYTK
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Event summary
Monashee Investment Management LLC reduced its stake in Cytokinetics, Incorporated by 25% in the fourth quarter, selling 25,000 shares and retaining 75,000 shares valued at $4.77 million. Despite this insider selling and some other insider transactions, analysts maintain a "Moderate Buy" rating with an average target price of $99.30 for CYTK, which reported strong revenue growth in its latest quarter. The biopharmaceutical company focuses on novel small-molecule therapeutics for muscle function, with its lead program, omecamtiv mecarbil, targeting heart failure.